Effectiveness of non-pharmaceutical public health interventions against COVID-19: A systematic review and meta-analysis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
05
2021
accepted:
08
11
2021
entrez:
23
11
2021
pubmed:
24
11
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Non-Pharmaceutical Public Health Interventions (NPHIs) have been used by different countries to control the spread of the COVID-19. Despite available evidence regarding the effectiveness of NPHSs, there is still no consensus about how policymakers can trust these results. Studies on the effectiveness of NPHSs are single studies conducted in specific communities. Therefore, they cannot individually prove if these interventions have been effective in reducing the spread of the infection and its adverse health outcomes. In this systematic review, we aimed to examine the effects of NPHIs on the COVID-19 case growth rate, death growth rate, Intensive Care Unit (ICU) admission, and reproduction number in countries, where NPHIs have been implemented. We searched relevant electronic databases, including Medline (via PubMed), Scopus, CINAHL, Web of Science, etc. from late December 2019 to February 1, 2021. The key terms were primarily drawn from Medical Subject Heading (MeSh and Emtree), literature review, and opinions of experts. Peer-reviewed quasi-experimental studies were included in the review. The PROSPERO registration number is CRD42020186855. Interventions were NPHIs categorized as lockdown, stay-at-home orders, social distancing, and other interventions (mask-wearing, contact tracing, and school closure). We used PRISMA 2020 guidance for abstracting the data and used Cochrane Effective Practice and Organization of Practice (EPOC) Risk of Bias Tool for quality appraisal of the studies. Hartung-Knapp-Sidik-Jonkman random-effects model was performed. Main outcomes included COVID-19 case growth rate (percentage daily changes), COVID-19 mortality growth rate (percentage daily changes), COVID-19 ICU admission (percentage daily changes), and COVID-19 reproduction number changes. Our search strategies in major databases yielded 12,523 results, which decreased to 7,540 articles after eliminating duplicates. Finally, 35 articles qualified to be included in the systematic review among which 23 studies were included in the meta-analysis. Although studies were from both low-income and high-income countries, the majority of them were from the United States (13 studies) and China (five studies). Results of the meta-analysis showed that adoption of NPHIs has resulted in a 4.68% (95% CI, -6.94 to -2.78) decrease in daily case growth rates, 4.8% (95 CI, -8.34 to -1.40) decrease in daily death growth rates, 1.90 (95% CI, -2.23 to -1.58) decrease in the COVID-19 reproduction number, and 16.5% (95% CI, -19.68 to -13.32) decrease in COVID-19 daily ICU admission. A few studies showed that, early enforcement of lockdown, when the incidence rate is not high, contributed to a shorter duration of lockdown and a lower increase of the case growth rate in the post-lockdown era. The majority of NPHIs had positive effects on restraining the COVID-19 spread. With the problems that remain regarding universal access to vaccines and their effectiveness and considering the drastic impact of the nationwide lockdown and other harsh restrictions on the economy and people's life, such interventions should be mitigated by adopting other NPHIs such as mass mask-wearing, patient/suspected case isolation strategies, and contact tracing. Studies need to address the impact of NPHIs on the population's other health problems than COVID-19.
Identifiants
pubmed: 34813628
doi: 10.1371/journal.pone.0260371
pii: PONE-D-21-17248
pmc: PMC8610259
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0260371Commentaires et corrections
Type : UpdateOf
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur J Hum Genet. 2020 Jun;28(6):719-723
pubmed: 32415272
Ethn Health. 2021 Jan;26(1):22-35
pubmed: 33334160
Indian J Public Health. 2020 Jun;64(Supplement):S142-S146
pubmed: 32496246
Nature. 2020 Aug;584(7820):262-267
pubmed: 32512578
Nat Med. 2021 Jan;27(1):86-93
pubmed: 33257893
Sci Total Environ. 2020 Jul 10;725:138539
pubmed: 32304973
PLoS One. 2020 Sep 16;15(9):e0239026
pubmed: 32936811
Eur J Med Res. 2020 Nov 10;25(1):56
pubmed: 33168104
BMC Public Health. 2020 Nov 26;20(1):1806
pubmed: 33243199
Public Health. 2020 Dec;189:54-59
pubmed: 33160088
PLoS Med. 2016 Aug 16;13(8):e1002109
pubmed: 27529422
JAMA. 2020 Sep 1;324(9):859-870
pubmed: 32745200
S Afr Med J. 2020 Oct 28;110(11):1119-1123
pubmed: 33403990
Sci Total Environ. 2020 Jul 20;727:138761
pubmed: 32330703
JAMA. 2020 Jun 23;323(24):2522-2524
pubmed: 32459287
Nonlinear Dyn. 2020 Aug 27;:1-11
pubmed: 32874016
JAMA Intern Med. 2020 Oct 1;180(10):1336-1344
pubmed: 32609310
Colomb Med (Cali). 2020 Jun 30;51(2):e4266
pubmed: 33012884
BMC Health Serv Res. 2018 Sep 6;18(1):692
pubmed: 30189897
JMIR Med Inform. 2020 Aug 25;8(8):e20992
pubmed: 32784189
Nat Rev Microbiol. 2021 Mar;19(3):171-183
pubmed: 33057203
Eur J Dev Res. 2020 Nov 2;:1-34
pubmed: 33162688
JAMA Netw Open. 2020 May 1;3(5):e2011102
pubmed: 32413112
J Infect. 2020 Jun;80(6):e32-e33
pubmed: 32209383
Cad Saude Publica. 2020 Oct 19;36(10):e00213920
pubmed: 33084836
PLoS Med. 2020 Aug 11;17(8):e1003244
pubmed: 32780772
J Infect Dis. 2010 Feb 15;201(4):491-8
pubmed: 20088690
Infect Dis Poverty. 2020 Sep 16;9(1):130
pubmed: 32938502
PLoS One. 2020 Jul 30;15(7):e0236619
pubmed: 32730356
JMIR Mhealth Uhealth. 2020 Apr 27;8(4):e19139
pubmed: 32310817
J Infect. 2021 Jan;82(1):133-142
pubmed: 33275956
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
JAMA Netw Open. 2020 Oct 1;3(10):e2026010
pubmed: 33095253
Risk Manag Healthc Policy. 2020 Sep 23;13:1695-1700
pubmed: 33061703
Int J Environ Res Public Health. 2020 Sep 13;17(18):
pubmed: 32933172
Rev Bras Epidemiol. 2020 Jun 22;23:e200056
pubmed: 32578811
EClinicalMedicine. 2020 Aug;25:100466
pubmed: 32840492
J Med Internet Res. 2020 Dec 21;22(12):e24614
pubmed: 33302253
J Korean Med Sci. 2020 Sep 07;35(35):e321
pubmed: 32893522
Am J Infect Control. 2020 Aug;48(8):958-960
pubmed: 32461066
Arch Iran Med. 2020 Nov 01;23(11):776-781
pubmed: 33220696
BMJ Open. 2020 Dec 10;10(12):e041778
pubmed: 33303462
Sci Rep. 2021 Jan 18;11(1):1661
pubmed: 33462369
PLoS One. 2020 Jul 29;15(7):e0236779
pubmed: 32726363
Front Med. 2020 Oct;14(5):623-629
pubmed: 32495288
PLoS Negl Trop Dis. 2020 Jul 13;14(7):e0008484
pubmed: 32658925
Clin Infect Dis. 2020 Sep 12;71(6):1454-1460
pubmed: 32255183
Explor Res Hypothesis Med. 2020 Jul 8;:1-10
pubmed: 32734759
JAMA Netw Open. 2020 Jul 1;3(7):e2016099
pubmed: 32701162
World J Clin Cases. 2020 Jul 26;8(14):2959-2976
pubmed: 32775378
BMJ. 2021 Mar 29;372:n160
pubmed: 33781993
Health Aff (Millwood). 2020 Jul;39(7):1237-1246
pubmed: 32407171
Science. 2020 May 1;368(6490):493-497
pubmed: 32213647
One Health. 2020 Dec;10:100160
pubmed: 32864409
Public Health. 2020 Aug;185:27-29
pubmed: 32526559
Geroscience. 2020 Aug;42(4):1075-1082
pubmed: 32529592
JAMA. 2020 May 19;323(19):1915-1923
pubmed: 32275295
PLoS One. 2020 Sep 29;15(9):e0239554
pubmed: 32991604
MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1691-1694
pubmed: 33180757